Switzerland-based biopharma start-up Enzyvant has gained a double fast track status from the FDA for its new rare disease candidate RVT-802. The investigational tissue-based therapy is for the ...
Gildeuretinol (ALK-001; Alkeus Pharmaceuticals) has received Rare Pediatric Disease and Fast Track Designations from the FDA for the treatment of Stargardt disease, according to an announcement from ...
Gildeuretinol (ALK-001) received FDA Rare Pediatric Disease and Fast Track designations for Stargardt disease, highlighting its potential as a groundbreaking therapy. Clinical trials, TEASE-1 and ...